Soley Therapeutics
Soley Therapeutics is a pioneering drug discovery and development company leveraging a proprietary high-throughput platform that decodes cellular language at scale. Founded in 2020 by cardiologist Yerem Yeghiazarians, MD, and molecular cancer biologist Kurosh Ameri, PhD, the company uses AI/ML to interpret nuanced cellular responses through a target-agnostic lens, enabling efficient identification of novel drug candidates. Their platform harnesses cells as natural sensors to accelerate drug discovery, with a pipeline of over 50 active compounds and three patentable novel chemical entities discovered within 14 months. Soley Therapeutics combines interdisciplinary expertise and advanced automation to revolutionize life sciences R&D productivity and drug development efficiency, positioning itself as a leader in innovative therapeutics addressing unmet patient needs.
Soley Therapeutics
Soley Therapeutics is a pioneering drug discovery and development company leveraging a proprietary high-throughput platform that decodes cellular language at scale. Founded in 2020 by cardiologist Yerem Yeghiazarians, MD, and molecular cancer biologist Kurosh Ameri, PhD, the company uses AI/ML to interpret nuanced cellular responses through a target-agnostic lens, enabling efficient identification of novel drug candidates. Their platform harnesses cells as natural sensors to accelerate drug discovery, with a pipeline of over 50 active compounds and three patentable novel chemical entities discovered within 14 months. Soley Therapeutics combines interdisciplinary expertise and advanced automation to revolutionize life sciences R&D productivity and drug development efficiency, positioning itself as a leader in innovative therapeutics addressing unmet patient needs.